JPMorgan发展中市场股票主动型ETF JADE 深 沪
等待开盘 10-01 09:30:00 美东时间
79.0665
-0.704
-0.88%
华盛通- 最 高79.36
- 今 开79.7703
- 成交量 2265股
- 最 低 78.76
- 昨 收 79.7703
- 总市值 3162.66万
- 52周最高 82.75
- 市盈率 静 --
- 换手率 0.57%
- 52周最低 58.6212
- 委 比 0.00%
- 总股本 40.00万
- 历史最高 82.75
- 量 比 1.50
- 振 幅 0.75%
- 历史最低 40.7433
- 每 手 1
- 风险率 7.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jade Biosciences advances JADE301 toward Phase 1 trial
The latest announcement is out from Jade Biosciences ( ($JBIO) ). On September ...
09-30 19:28
Jade Biosciences, Inc. GAAP EPS of -$0.76
Jade Biosciences, Inc. press release (JBIO): Q2 GAAP EPS of -$0.76. Cash Position: As of June 30, 2026, Jade had cash, cash equivalents, and investments of $461.2 million. Based on its current operati...
08-11 01:37
Jade Biosciences plans public offering, pre-funded warrants
Jade Biosciences (JBIO) on Wednesday said it intends to offer shares of common stock and, in lieu of common stock for certain investors, pre-funded warrants in an underwritten public offering. The com...
06-04 04:26
Why Is Jade Biosciences Stock Trading Lower On Monday?
Jade Biosciences reports Phase 1 JADE101 data showing sustained IgA reductions in IgAN, while analyst addresses ADA concerns and timeline expectations.
06-02 01:59
Jade Biosciences Doses First Patient In Phase 1 Clinical Study Of JADE201; Anticipates Interim First-In-Human Data Next Year
Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the first participant has
05-27 04:06
业聚医疗（6929.HK）：全年业绩再创新高，核心经营利润增20.2%，全球化与创新双轮驱动彰显韧性
2025年，全球医疗器械行业仍在关税扰动与地缘政治变局中艰难前行。业聚医疗却逆势交出一份硬核成绩单：收入与销量连续五年创下历史新高，核心经营利润同比猛增20....
03-16 08:51
Jade Biosciences Provides Pipeline Update: JADE101 Phase 1 Ongoing, Phase 2 In IgA Nephropathy Mid-26; JADE201 First-In-Human RA Study 2Q26; JADE301 Nominated With Phase 1 Planned 1H27
JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026;
01-05 20:14
